Canaccord Genuity Starts BioXcel Therapeutics (BTAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
UBS Starts BioXcel Therapeutics (BTAI) at Buy
April 2, 2018 6:51 AM EDTUBS initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $18.00.
For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.
Shares of BioXcel Therapeutics closed at $10.24 Friday.
... MoreBarclays Starts BioXcel Therapeutics (BTAI) at Overweight
April 2, 2018 4:26 AM EDTBarclays initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Overweight rating and a price target of $15.00.
Analyst Geoff Meacham says the company is a unique play in both neurology and oncology as well as AI and sees good potential for shares... More
BMO Capital Starts BioXcel Therapeutics (BTAI) at Outperform
April 2, 2018 4:23 AM EDTBMO Capital initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Outperform rating and a price target of $23.00.
Analyst Do Kim comments "We believe BXCL501's sublingual formulation and favorable efficacy/safety profile will enable BioXcel to consolidate a highly fragmented market in... More
